Compare Krispy Kreme Inc (DNUT) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Krispy Kreme Inc vs Sanofi SA — how do they compare? Krispy Kreme Inc trades at $2.98 (market cap $521.37M), while Sanofi SA trades at $40.15 (market cap $95.18B). The key difference: Sanofi SA is far larger — about 182.6× Krispy Kreme Inc's market cap, and Sanofi SA pays the higher dividend (6.01%). Which is the better fit depends on your goals — on Pluang, investors hold Krispy Kreme Inc for 46 Days and Sanofi SA for 94 Days on average.
| DNUT | SNY | |
|---|---|---|
Market Cap | $521.37M | $95.18B |
Volume | 2,293,015 | 2,995,646 |
Sector | Consumer Staples | Health |
52-Week High | $4.70 | $52.34 |
52-Week Low | $2.87 | $39.51 |
Typical Hold Time | 46 Days | 94 Days |
Enterprise Value | $1.76B | $114.48B |
Dividend Yield | 3.47% | 6.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Krispy Kreme (DNUT) trades at $2.945, up 0.86% with a bullish technical signal despite mixed earnings. The company shows strong gross margins (75.19%) but negative net income (-$515.77M for 2025) and declining revenue trends. Analyst sentiment is positive with 50% buy ratings, though recent news highlights ongoing legal investigations into fiduciary duties.
Investment outlook remains cautious due to profitability challenges and legal overhangs, offset by low valuation multiples (P/S 0.35) and product innovation. Key risks include sustained losses, debt burden, and litigation outcomes. Upside depends on margin improvement and successful new launches.
SNY trades at $40.17, down slightly by 0.07%. The technical outlook is bearish, with price near key support at $40. Fundamentally, the company reported strong Q2 2026 earnings, beating estimates with EPS of $1.21, and revenue for 2025 reached $46.72B. Recent news highlights a significant $8B immunology alliance expansion with Regeneron, signaling growth potential beyond its blockbuster drug Dupixent.
The stock presents a mixed outlook. Positive factors include consistent earnings beats, a high gross margin of 72.77%, and strategic partnerships. However, a bearish technical signal, a projected net income decline to $4.0B in 2026, and a high proportion of analyst hold ratings (51.86%) suggest caution. Key risks involve execution of new drug pipelines and future patent expirations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Krispy Kreme Inc
Krispy Kreme Inc is a sweet treat brands company. The company's Original Glazed doughnut is recognized for its hot-off-the-line, melt-in- your-mouth experience. It operates in 30 countries through its network of fresh Doughnut Shops, partnerships with retailers, and a growing ecommerce and delivery business. The company conducts its business through the following three reported segments namely U.S. and Canada, includes all operations in the U.S. and Canada, Insomnia Cookies shops, and the Branded Sweet Treat Line
Read more on DNUT →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
